INBX.US Inhibrx Biosciences, Inc.

Healthcare Biotechnology USA Stocks
83.30 USD
Close of Nov 15, 2026
57.30 155.29
Market cap
USD 1.23B
P/E
-
P/B
7.41x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is INBX.US undervalued?

Graham number

The Graham number of Inhibrx Biosciences, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Inhibrx Biosciences, Inc. fundamental analysis

No fundamental analysis for Inhibrx Biosciences, Inc. yet.

Inhibrx Biosciences, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tum…

Full company profile